Xovoltib (Afatinib) tablets are manufactured by Boehringer Ingelheim.
Xovoltib (Afatinib) tablets are available in 20mg, 30mg, 40mg & 50mg strength
Xovoltib (Afatinib) tablets comes in a box of 4 strips of 7 tablets each.
Xovoltib (Afatinib) has received regulatory approval for use as a treatment for non-small cell lung cancer, although there is emerging evidence to support Xovoltib's (Afatinib) use in other cancers such as breast cancer. Xovoltib (Afatinib) is not a chemotherapy drug but one of what are termed "targeted therapies." Targeted therapy is the result of years of research dedicated to understanding the differences between cancer cells and normal cells. Xovoltib (Afatinib) is designed to block tumor cell growth in several ways. Xovoltib (Afatinib) blocks the activating sites (called tyrosine kinases) of several proteins within the cell. These proteins are most likely to stimulate cancer growth when the tumor contains the EGFR gene mutation. By blocking these targets, it is hoped the cancer will shrink.